OBJECTIVE: To determine the effect of an interventional program designed to improve adherence to American Academy of Pediatrics (AAP) guidelines for palivizumab prophylaxis. METHODS: The study was carried out at the Children's Hospital, University of California, Irvine Medical Center and its affiliated clinics. An interventional program focusing on education of health care workers on AAP guidelines, updating health care providers about respiratory syncytial virus (RSV) activity, as well as designating a single clinic with effective screening of referrals for administration of palivizumab, was implemented during the summer of 2004. The medical records of infants who had received at least 1 dose of palivizumab or were eligible to receive palivizumab during the 2003-2004 and the 2004-2005 RSV seasons at the University of California, Irvine Medical Center were reviewed. The proportion of patients who received injections according to AAP guidelines was compared. RESULTS: After the intervention, the proportion of patients who received palivizumab injections according to AAP recommendations increased from 39% to 61% (P < 0.0001). The program decreased the proportion of unnecessary injections significantly (140/525, or 27%, in 2003-2004 to 33/323, or 10%, in 2004-2005; P < 0.0001) but did not change the proportion of missing injections. The program resulted in a significant drop (14% to 2%; P < 0.0001) in proportion of palivizumab injections that were given too late, when RSV activity had subsided. RSV hospitalization rates did not change as a result of the intervention. CONCLUSIONS: Our interventional program improved adherence to AAP guidelines mainly by decreasing the unnecessary palivizumab injections.
OBJECTIVE: To determine the effect of an interventional program designed to improve adherence to American Academy of Pediatrics (AAP) guidelines for palivizumab prophylaxis. METHODS: The study was carried out at the Children's Hospital, University of California, Irvine Medical Center and its affiliated clinics. An interventional program focusing on education of health care workers on AAP guidelines, updating health care providers about respiratory syncytial virus (RSV) activity, as well as designating a single clinic with effective screening of referrals for administration of palivizumab, was implemented during the summer of 2004. The medical records of infants who had received at least 1 dose of palivizumab or were eligible to receive palivizumab during the 2003-2004 and the 2004-2005 RSV seasons at the University of California, Irvine Medical Center were reviewed. The proportion of patients who received injections according to AAP guidelines was compared. RESULTS: After the intervention, the proportion of patients who received palivizumab injections according to AAP recommendations increased from 39% to 61% (P < 0.0001). The program decreased the proportion of unnecessary injections significantly (140/525, or 27%, in 2003-2004 to 33/323, or 10%, in 2004-2005; P < 0.0001) but did not change the proportion of missing injections. The program resulted in a significant drop (14% to 2%; P < 0.0001) in proportion of palivizumab injections that were given too late, when RSV activity had subsided. RSV hospitalization rates did not change as a result of the intervention. CONCLUSIONS: Our interventional program improved adherence to AAP guidelines mainly by decreasing the unnecessary palivizumab injections.
Authors: Jennifer W Chow; Michael F Chicella; Anthony M Christensen; Carolyn S Moneymaker; John Harrington; James E Dice Journal: J Pediatr Pharmacol Ther Date: 2017 Sep-Oct
Authors: Kecia N Carroll; Marie R Griffin; Kathryn M Edwards; Asad Ali; Yuwei Zhu; Marika K Iwane; Peter G Szilagyi; Mary A Staat; Timothy P Stevens; Caroline B Hall; John V Williams; Tina V Hartert Journal: Pediatr Infect Dis J Date: 2012-11 Impact factor: 2.129
Authors: Keyur A Dave; Emma L Norris; Alexander A Bukreyev; Madeleine J Headlam; Ursula J Buchholz; Toshna Singh; Peter L Collins; Jeffrey J Gorman Journal: Mol Cell Proteomics Date: 2014-08-08 Impact factor: 5.911
Authors: L H Utidjian; A Hogan; J Michel; A R Localio; D Karavite; L Song; M J Ramos; A G Fiks; S Lorch; R W Grundmeier Journal: Appl Clin Inform Date: 2015-12-30 Impact factor: 2.342
Authors: Marcus L Hastie; Madeleine J Headlam; Nirav B Patel; Alexander A Bukreyev; Ursula J Buchholz; Keyur A Dave; Emma L Norris; Cassandra L Wright; Kirsten M Spann; Peter L Collins; Jeffrey J Gorman Journal: Mol Cell Proteomics Date: 2012-02-08 Impact factor: 5.911